体外診断薬市場 : 2029年までの世界予測

出版：MarketsandMarkets（マーケッツアンドマーケッツ）　出版年月：2024年3月

In Vitro Diagnostics Market – Global Forecast to 2029

体外診断薬市場 : 製品とサービス (機器、キット、ソフトウェア)、技術 (免疫測定、血液学、尿検査)、検体 (血液、唾液)、検査の種類、用途 (腫瘍学、自己免疫、CVD、感染症) – 2029年までの世界予測
In Vitro Diagnostics Market by Product & Service (Instruments, Kits, Software), Technology (Immunoassay, Hematology, Urinalysis), Specimen (Blood, Saliva), Test Type, Application (Oncology, Autoimmune, CVD, Infectious Diseases) – Global Forecast to 2029

お問合せ・ご注文　　出版社・価格・納期について

Report Overview

The global in vitro diagnostics market is projected to reach USD 119.4 billion by 2029 from USD 85.2 billion in 2024, at a CAGR of 6.9% during the forecast period.

世界の体外診断薬市場は、予測期間中のCAGR 6.9%で、2024年の852億米ドルから2029年までに1,194億米ドルに達すると予測されています。

With the rapid growth in the geriatric population globally, the prevalence of age-associated diseases is expected to increase significantly. Chronic conditions that include diabetes, cancer, and cardiovascular disease are more common in old age. As these diseases need to be continuously monitored and managed, there is an increasing need for diagnostic tests. Also, due to a weakened immune system, people get increasingly susceptible to several infectious diseases. Effective treatment of infectious diseases depends on early detection, which made possible by IVD tests. Hence, this factor is significantly inducing growth of the IVD market.

“Molecular diagnostics (MDx) segment is projected to witness highest growth rate in the in vitro diagnostics market, by technology, during the forecast period.”
Based on the technology the IVD market is bifurcated into immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and chromatography & mass spectrometry. The molecular diagnostics (MDx) segment is estimated to register the highest growth rate during the forecast period. Growth in this market is majorly driven by the rising prevalence of infectious diseases, cancer, and various genetic disorders; growing demand for blood screening; and increasing applications of molecular diagnostic technologies in pharmacogenetics and point-of-care testing.

“Endocrinology segment is projected to register highest growth rate in the in vitro diagnostics market, by application, during the forecast period.”
The IVD market is bifurcated into infectious diseases, oncology, endocrinology, cardiology, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing, bone & mineral disorders, coagulation testing, blood group typing, and other applications. The endocrinology segment is expected to grow at the highest rate within the in vitro diagnostics market. Technological advancements, the increasing incidence of diabetes and thyroid disorders, changing lifestyles, and the availability of home tests to control these medical conditions are the major drivers for the growth of the IVD market for endocrinology applications.

“Asia Pacific: The fastest-growing region in vitro diagnostics market.”
The global IVD market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. The Asia Pacific market is estimated to witness the highest growth rate during the forecast period. The rising healthcare spending, rapidly growing geriatric populations, and increasing disposable income make this region a lucrative market for growth opportunities.

The break-up of the profile of primary participants in the IVD market:

• By Company Type: Tier 1 – 42%, Tier 2 – 30%, and Tier 3 – 28%
• By Designation: C-level – 46%, D-level – 23%, and Others – 31%
• By Region: North America – 23%, Europe – 45%, Asia Pacific – 28.3%, Latin America- 3%, Middle East & Africa – 0.8%, GCC Countries – 1.3%

The key players in this market are Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers (Germany), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Qiagen N.V. (Netherlands), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Illumina, Inc. (US), Hologic, Inc. (US), Revvity (US), Griffols (Spain), Werfen (Spain), Devyser (Sweden), Chembio Diagnostics, Inc. (US). Surmodics, Inc. (US), Menarini Silicon Biosystems (Italy), SpeeDx Pty. Ltd. (Australia), GENSPEED Biotech GmbH (Austria), Accelerate Diagnostics, Inc. (US), Merck KGaA (Germany), Caris Life Sciences, Inc (US), Cellabs (Australia), J. Mitra & Co. Pvt. Ltd. (India), Epitope Diagnostics (US), Boster Biological Technology (US), Enzo Biochem (US), Genetic Signatures (Australia), Savyon Diagnostics (Israel), Trivitron Healthcare (India), mdxhealth (Belgium), Creative Diagnostics (US), InBios International, Inc. (US), Maccura Biotechnology Co., Ltd. (China), Vela Diagnostics (Singapore), and ARKRAY, Inc. (Japan)

Research Coverage:
This research report divided the in vitro diagnostics market by test type (PoC tests and laboratory tests), by technology (molecular diagnostics, immunoassays, coagulation & hemostasis, clinical chemistry, urinalysis, chromatography & mass spectrometry, microbiology, and hematology), by product & services (instruments, reagents & kits, and data management software and services), specimen (urine, saliva, blood, serum, and plasma, and other specimens), by end user (pharmaceutical & biotechnology companies, hospital & clinics, blood banks, academic institutes, clinical laboratories, home care settings, and other end users), by application (endocrinology, cardiology, blood screening, blood group typing, autoimmune diseases, bone & mineral disorders, oncology, coagulation testing, genetic testing, infectious diseases, allergy diagnostics, drug monitoring & testing, and other applications), and by region (Latin America, the GCC Countries, Europe, Middle East & Africa, Asia Pacific, and North America)
The report’s coverage includes comprehensive details about the key factors impacting the growth of the IVD market, including opportunities, challenges, opportunities, and restraints. To offer insights into their business overview, products offered, significant strategies, acquisitions and partnerships, product launches, and recent developments related to the IVD market, a thorough analysis of the major industry players has been conducted. This study examines the competitive landscape of emerging in vitro diagnostics startups.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall in vitro diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:
• Analysis of key drivers: (Increasing geriatric population and subsequent rise in chronic & infectious diseases, and Emergence of rapid PoC diagnostics), restraints (Unfavorable reimbursement scenario for IVD market), opportunities (Introduction of disease-specific biomarkers and tests, and Growth opportunities in emerging markets), and challenges (Operational barriers to the IVD market) influencing the growth of the in vitro diagnostics market.
• Product Development/Innovation: Detailed insights on research & development activities, and new product launches and approvals in the in vitro diagnostics market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the in vitro diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the IVD market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US) among others in the IVD market strategies.

Table of Contents

1            INTRODUCTION            82

1.1         STUDY OBJECTIVES      82

1.2         MARKET DEFINITION   82

1.3         INCLUSIONS & EXCLUSIONS     83

1.4         MARKET SCOPE             84

1.4.1      MARKETS COVERED     84

FIGURE 1           MARKET SEGMENTATION         84

1.4.2      REGIONS COVERED      85

1.4.3      YEARS CONSIDERED     85

1.4.4      CURRENCY CONSIDERED          86

1.5         MARKET STAKEHOLDERS          86

1.6         SUMMARY OF CHANGES            86

1.6.1      MARKET RECONCILIATION:      87

1.7         RECESSION IMPACT      87

2            RESEARCH METHODOLOGY     88

2.1         RESEARCH DATA           88

FIGURE 2           RESEARCH DESIGN       88

2.1.1      SECONDARY RESEARCH             89

2.1.1.1   Key data from secondary sources     90

2.1.2      PRIMARY DATA 90

2.1.2.1   Primary sources   91

2.1.2.2   Key data from primary sources         91

2.1.2.3   Key industry insights          93

FIGURE 3           BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 93

FIGURE 4           BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION    94

2.2         MARKET SIZE ESTIMATION       94

2.2.1      BOTTOM-UP APPROACH           94

2.2.1.1   Approach 1: Company revenue estimation approach    95

FIGURE 5           REVENUE SHARE ANALYSIS       95

FIGURE 6           CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS   96

FIGURE 7           IN VITRO DIAGNOSTICS MARKET: TOP-DOWN APPROACH              97

2.3         MARKET BREAKDOWN AND DATA TRIANGULATION    98

FIGURE 8           DATA TRIANGULATION METHODOLOGY         98

2.4         MARKET SHARE ANALYSIS         99

2.5         STUDY ASSUMPTIONS  99

2.6         GROWTH RATE ASSUMPTIONS 99

2.7         RESEARCH LIMITATIONS           99

2.7.1      METHODOLOGY-RELATED LIMITATIONS         99

2.7.2      SCOPE-RELATED LIMITATIONS             100

2.8         RISK ASSESSMENT         100

TABLE 1             RISK ASSESSMENT ANALYSIS    100

2.9         RECESSION IMPACT ANALYSIS 100

3            EXECUTIVE SUMMARY 101

FIGURE 9           IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)     101

FIGURE 10         IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)     102

FIGURE 11         IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2024 VS. 2029 (USD MILLION) 103

FIGURE 12         IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION) 103

FIGURE 13         IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)     104

FIGURE 14         IN VITRO DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 105

FIGURE 15         GEOGRAPHIC SNAPSHOT OF IVD MARKET        106

4            PREMIUM INSIGHTS      107

4.1         IN VITRO DIAGNOSTICS MARKET OVERVIEW   107

FIGURE 16         GROWING FOCUS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET            107

4.2         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2023) 108

FIGURE 17         REAGENTS & KITS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 108

4.3         IN VITRO DIAGNOSTICS MARKET: REGIONAL MIX         108

FIGURE 18         ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD       108

4.4         IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES           109

FIGURE 19         CHINA AND INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD       109

4.5         IN VITRO DIAGNOSTICS MARKET: EMERGING ECONOMIES VS. DEVELOPED ECONOMIES          110

FIGURE 20         EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD         110

5            MARKET OVERVIEW     111

5.1         INTRODUCTION            111

5.2         MARKET DYNAMICS     111

FIGURE 21         IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    111

5.2.1      DRIVERS            112

5.2.1.1   Increasing geriatric population and subsequent rise in chronic & infectious diseases 112

TABLE 2             ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2022−2050)    112

5.2.1.2   Gradual shift from centralized testing to point-of-care testing    113

5.2.1.3   Growing awareness of early disease diagnosis in emerging economies      114

5.2.1.4   Emergence of rapid PoC technologies and rising adoption of automated analyzers              115

TABLE 3             IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES (2021−2023)      115

5.2.1.5   Growing preference for personalized medicine            115

5.2.1.6   Increasing funding for R&D activities            116

5.2.2      RESTRAINTS     116

5.2.2.1   Unfavorable reimbursements           116

5.2.2.2   Stringent regulatory requirements   117

FIGURE 22         IVDR: CRITICAL AREAS OF IMPACT        117

5.2.2.3   High cost of diagnostic equipment   118

5.2.3      OPPORTUNITIES           118

5.2.3.1   Introduction of disease-specific biomarkers and tests   118

TABLE 4             APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE         118

5.2.3.2   Growing significance of companion diagnostics           119

5.2.3.3   Growth opportunities in emerging markets    120

TABLE 5             RECENT DEVELOPMENTS IN EMERGING MARKETS       120

5.2.3.4   Improvements in immunoassay diagnostic technologies             121

5.2.3.5   Trend of digitalization       121

5.2.4      CHALLENGES   122

5.2.4.1   Operational barriers          122

TABLE 6             IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES        122

5.3         PRICING ANALYSIS        123

5.3.1      INDICATIVE AVERAGE SELLING PRICE OF REAGENTS & KITS (USD), BY REGION             123

5.3.2      AVERAGE SELLING PRICE OF IMMUNOASSAY ANALYZERS (USD)              123

5.3.3      AVERAGE SELLING PRICE OF LATERAL FLOW ANALYZERS (USD)              124

5.3.4      AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS (USD)              124

5.3.5      AVERAGE SELLING PRICE OF CLINICAL CHEMISTRY ANALYZERS (USD)              125

5.4         VALUE CHAIN ANALYSIS            126

FIGURE 23         IN VITRO DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS              127

5.5         SUPPLY CHAIN ANALYSIS          127

FIGURE 24         IN VITRO DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS              128

5.6         PORTER’S FIVE FORCES ANALYSIS         128

TABLE 7             IN VITRO DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS          128

5.6.1      INTENSITY OF COMPETITIVE RIVALRY 129

5.6.2      BARGAINING POWER OF SUPPLIERS     129

5.6.3      BARGAINING POWER OF BUYERS           129

5.6.4      THREAT OF NEW ENTRANTS    129

5.6.5      THREAT OF SUBSTITUTES         129

5.7         ECOSYSTEM ANALYSIS 130

FIGURE 25         IN VITRO DIAGNOSTICS MARKET: ECOSYSTEM MAP     130

5.7.1      IN VITRO DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM            131

5.8         REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          131

TABLE 8             LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 131

5.9         REGULATORY ANALYSIS            132

5.9.1      NORTH AMERICA          132

5.9.1.1   US         132

TABLE 9             US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES              132

FIGURE 26         US: REGULATORY PROCESS FOR IVD DEVICES  133

5.9.1.2   Canada  134

FIGURE 27         CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA            134

5.9.2      EUROPE             134

TABLE 10           EUROPE: CLASSIFICATION OF IVD DEVICES      135

FIGURE 28         EUROPE: IVDR TIMELINE           135

5.9.3      ASIA PACIFIC    136

5.9.3.1   Japan     136

FIGURE 29         REGULATORY PROCESS FOR IVD DEVICES IN JAPAN     136

TABLE 11           JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN   137

TABLE 12           JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS           137

5.9.3.2   China     137

TABLE 13           CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS           137

5.9.3.3   India      138

FIGURE 30         INDIA: REGULATORY PROCESS FOR IVD DEVICES          138

5.9.3.4   South Korea        138

TABLE 14           SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS          138

5.9.3.5   Indonesia             139

TABLE 15           INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES              139

5.9.4      RUSSIA 139

TABLE 16           RUSSIA: CLASSIFICATION OF IVD DEVICES        140

5.9.5      MIDDLE EAST & AFRICA             140

5.9.5.1   Saudi Arabia        140

TABLE 17           SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS          140

5.9.5.2   Africa    141

5.9.6      LATIN AMERICA             141

5.9.6.1   Mexico  141

FIGURE 31         MEXICO: REGULATORY PROCESS FOR IVD DEVICES      141

TABLE 18           MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS           142

5.9.6.2   Brazil     142

5.10       PATENT ANALYSIS        143

5.11       TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 145

5.11.1    REVENUE SHIFT FOR IN VITRO DIAGNOSTICS MARKET 145

5.12       KEY CONFERENCES & EVENTS  146

TABLE 19           IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2024)            146

5.13       TECHNOLOGY ANALYSIS           146

5.13.1    IN VITRO DIAGNOSTICS MARKET: KEY TECHNOLOGIES            146

5.13.2    IN VITRO DIAGNOSTICS MARKET: ADJACENT TECHNOLOGIES 147

5.14       KEY STAKEHOLDERS AND BUYING CRITERIA    148

5.14.1    KEY STAKEHOLDERS IN BUYING PROCESS         148

FIGURE 32         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR IVD PRODUCTS              148

TABLE 20           INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS (%) 149

5.14.2    BUYING CRITERIA         149

FIGURE 33         KEY BUYING CRITERIA FOR IVD PRODUCTS      149

TABLE 21           KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS       149

5.15       TRADE ANALYSIS          150

5.15.1    TRADE ANALYSIS FOR IVD PRODUCTS 150

TABLE 22           IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2018–2022 (USD MILLION) 150

TABLE 23           EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2018–2022 (USD MILLION) 150

6            IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE      151

6.1         INTRODUCTION            152

TABLE 24           IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)          152

6.2         REAGENTS & KITS          152

6.2.1      INCREASING DEMAND FOR RAPID AND POINT-OF-CARE DIAGNOSTICS TO DRIVE MARKET         152

TABLE 25           IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2021–2029 (USD MILLION)       154

TABLE 26           NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021–2029 (USD MILLION)      154

TABLE 27           EUROPE: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021–2029 (USD MILLION)  155

TABLE 28           ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021–2029 (USD MILLION)      155

TABLE 29           LATIN AMERICA: IN VITRO DIAGNOSTICS FOR REAGENTS & KITS, BY COUNTRY, 2021–2029 (USD MILLION)  156

TABLE 30           GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021–2029 (USD MILLION)      156

6.3         INSTRUMENTS 156

6.3.1      RISING TREND OF AUTOMATION TO DRIVE MARKET   156

TABLE 31           KEY INSTRUMENTS AVAILABLE IN IVD MARKET             157

TABLE 32           IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021–2029 (USD MILLION)       158

TABLE 33           NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2029 (USD MILLION)           158

TABLE 34           EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2029 (USD MILLION)           159

TABLE 35           ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2029 (USD MILLION)           159

TABLE 36           LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2029 (USD MILLION)           160

TABLE 37           GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2029 (USD MILLION)           160

6.4         DATA MANAGEMENT SOFTWARE AND SERVICES           160

6.4.1      ABILITY TO IMPROVE OPERATIONAL EFFICIENCY TO SUPPORT MARKET GROWTH        160

TABLE 38           KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN IVD MARKET             161

TABLE 39           IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY REGION, 2021–2029 (USD MILLION)         162

TABLE 40           NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021–2029 (USD MILLION) 162

TABLE 41           EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021–2029 (USD MILLION)          163

TABLE 42           ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021–2029 (USD MILLION)          163

TABLE 43           LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021–2029 (USD MILLION)          164

TABLE 44           GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021–2029 (USD MILLION)          164

7            IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY    165

7.1         INTRODUCTION            166

TABLE 45           IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)     166

7.2         IMMUNOASSAYS            166

TABLE 46           KEY IMMUNOASSAY ANALYZERS AVAILABLE IN IVD MARKET              167

TABLE 47           IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)             168

TABLE 48           IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2021–2029 (USD MILLION)       168

TABLE 49           NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)        169

TABLE 50           EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021–2029 ((USD MILLION)       169

TABLE 51           ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)        170

TABLE 52           LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)        170

TABLE 53           GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)        170

7.2.1      ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)    171

7.2.1.1   Utilization in viral disease diagnostics and drug discovery to boost demand              171

TABLE 54           KEY ELISA ANALYZERS AVAILABLE IN IVD MARKET       171

TABLE 55           IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY REGION, 2021–2029 (USD MILLION)     172

TABLE 56           NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021–2029 (USD MILLION) 172

TABLE 57           EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021–2029 (USD MILLION)    173

TABLE 58           ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021–2029 (USD MILLION)    173

TABLE 59           LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021–2029 (USD MILLION)            174

TABLE 60          GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021–2029 (USD MILLION)            174

7.2.2      CHEMILUMINESCENCE IMMUNOASSAYS           174

7.2.2.1   High sensitivity and wide detection range to fuel market            174

TABLE 61           KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET      175

TABLE 62           IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2021–2029 (USD MILLION)            176

TABLE 63           NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)          176

TABLE 64           EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)          177

TABLE 65           ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)          177

TABLE 66           LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)          178

TABLE 67           GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)          178

7.2.3      IMMUNOFLUORESCENCE ASSAYS          178

7.2.3.1   HIV antibody diagnosis in medical research to support market growth     178

TABLE 68           IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY REGION, 2021–2029 (USD MILLION)              179

TABLE 69           NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)              179

TABLE 70           EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)              180

TABLE 71           ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)              180

TABLE 72           LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)              181

TABLE 73           GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)              181

7.2.4      RAPID TESTS    181

7.2.4.1   Rising usage in emergency care to drive market           181

TABLE 74           KEY RAPID TESTS AVAILABLE IN IVD MARKET  182

TABLE 75           IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY REGION, 2021–2029 (USD MILLION)       182

TABLE 76           NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 183

TABLE 77           EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021–2029 (USD MILLION)            183

TABLE 78           ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021–2029 (USD MILLION)             184

TABLE 79           LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021–2029 (USD MILLION)             184

TABLE 80           GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 184

7.2.5      ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)      185

7.2.5.1   Rapid analysis of samples and high functionality to boost demand            185

TABLE 81           IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY REGION, 2021–2029 (USD MILLION)          185

TABLE 82           NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021–2029 (USD MILLION)         186

TABLE 83           EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021–2029 (USD MILLION)    186

TABLE 84           ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021–2029 (USD MILLION)            187

TABLE 85           LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021–2029 (USD MILLION)         187

TABLE 86           GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET ELISPOT, BY COUNTRY, 2021–2029 (USD MILLION)            187

7.2.6      WESTERN BLOTTING   188

7.2.6.1   Gold standard for result validation to boost demand    188

TABLE 87           KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN IVD MARKET            188

TABLE 88           IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY REGION, 2021–2029 (USD MILLION)  189

TABLE 89           NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2029 (USD MILLION) 189

TABLE 90           EUROPE: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2029 (USD MILLION)    190

TABLE 91           ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2029 (USD MILLION)    190

TABLE 92           LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2029 (USD MILLION) 191

TABLE 93           GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2029 (USD MILLION) 191

7.2.7      OTHER IMMUNOASSAY TECHNOLOGIES           191

TABLE 94           IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY REGION, 2021–2029 (USD MILLION)            192

TABLE 95           NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)          192

TABLE 96           EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)              193

TABLE 97           ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)              193

TABLE 98           LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)          194

TABLE 99           GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)          194

7.3         CLINICAL CHEMISTRY  194

TABLE 100         CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES          195

TABLE 101         CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES             195

TABLE 102         IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)       196

TABLE 103         IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2021–2029 (USD MILLION)  197

TABLE 104         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021–2029 (USD MILLION)            197

TABLE 105         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021–2029 (USD MILLION)   198

TABLE 106         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021–2029 (USD MILLION)   198

TABLE 107         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021–2029 (USD MILLION)            199

TABLE 108         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021–2029 (USD MILLION)            199

7.3.1      BASIC METABOLIC PANELS       199

7.3.1.1   Rising prevalence of diabetes to boost demand             199

TABLE 109         IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY REGION, 2021–2029 (USD MILLION) 200

TABLE 110         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021–2029 (USD MILLION)    200

TABLE 111         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021–2029 (USD MILLION) 201

TABLE 112         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021–2029 (USD MILLION) 201

TABLE 113         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021–2029 (USD MILLION) 202

TABLE 114         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021–2029 (USD MILLION) 202

7.3.2      LIVER PANELS  202

7.3.2.1   Rising prevalence of cirrhosis and viral hepatitis to fuel market  202

TABLE 115         IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY REGION, 2021–2029 (USD MILLION)       203

TABLE 116         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021–2029 (USD MILLION)            203

TABLE 117        EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021–2029 (USD MILLION)            204

TABLE 118         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021–2029 (USD MILLION)          204

TABLE 119         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021–2029 (USD MILLION)          205

TABLE 120         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021–2029 (USD MILLION)          205

7.3.3      RENAL PROFILES           205

7.3.3.1   Ability to monitor cytokines & chemokines in urine to propel market       205

TABLE 121         IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY REGION, 2021–2029 (USD MILLION)       206

TABLE 122         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)        206

TABLE 123         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)       207

TABLE 124         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)       207

TABLE 125         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)       208

TABLE 126         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)        208

7.3.4      LIPID PROFILES             208

7.3.4.1   Determination of total cholesterol and risk status for CVD to boost demand              208

TABLE 127         IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY REGION, 2021–2029 (USD MILLION)       209

TABLE 128         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)       209

TABLE 129         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)       210

TABLE 130         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)       210

TABLE 131         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)       211

TABLE 132         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)       211

7.3.5      THYROID FUNCTION PANELS  211

7.3.5.1   High incidence of thyroid-related disorders to support market growth     211

TABLE 133         IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY REGION, 2021–2029 (USD MILLION)          212

TABLE 134         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)              212

TABLE 135         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021–2029 (USD MILLION) 213

TABLE 136         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021–2029 (USD MILLION) 213

TABLE 137         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)              214

TABLE 138         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)              214

7.3.6      ELECTROLYTE PANELS 214

7.3.6.1   Ability to diagnose hypertension and heart failure to support uptake        214

TABLE 139         IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY REGION, 2021–2029 (USD MILLION)  215

TABLE 140         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021–2029 (USD MILLION)           215

TABLE 141         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021–2029 (USD MILLION)           216

TABLE 142         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021–2029 (USD MILLION)           216

TABLE 143         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021–2029 (USD MILLION)           217

TABLE 144         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021–2029 (USD MILLION)           217

7.3.7      SPECIALTY CHEMICAL TESTS   217

7.3.7.1   Inclusion of immunosuppressant drug monitoring and drugs of abuse to support market growth     217

TABLE 145         IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY REGION, 2021–2029 (USD MILLION)   218

TABLE 146         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 218

TABLE 147         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION)      219

TABLE 148         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 219

TABLE 149         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 220

TABLE 150         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 220

7.4         MOLECULAR DIAGNOSTICS      220

TABLE 151         KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN IVD MARKET      221

TABLE 152         IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        222

TABLE 153         IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2021–2029 (USD MILLION)  222

TABLE 154         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)  223

TABLE 155         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)             223

TABLE 156         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)  224

TABLE 157         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)  224

TABLE 158         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)  224

7.4.1      POLYMERASE CHAIN REACTION (PCR) 225

7.4.1.1   High specificity of RT-PCR tests to drive market         225

TABLE 159         KEY PCR INSTRUMENTS AVAILABLE IN IVD MARKET    226

TABLE 160         IN VITRO DIAGNOSTICS MARKET FOR PCR, BY REGION, 2021–2029 (USD MILLION)     226

TABLE 161         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021–2029 (USD MILLION)            226

TABLE 162         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021–2029 (USD MILLION)    227

TABLE 163         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021–2029 (USD MILLION)    227

TABLE 164         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021–2029 (USD MILLION)            228

TABLE 165         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021–2029 (USD MILLION)            228

7.4.2      ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)              228

7.4.2.1   Cost benefits to drive market           228

TABLE 166         IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021–2029 (USD MILLION)          229

TABLE 167         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021–2029 (USD MILLION)             230

TABLE 168         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021–2029 (USD MILLION)    230

TABLE 169         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021–2029 (USD MILLION)            231

TABLE 170        LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021–2029 (USD MILLION)            231

TABLE 171         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021–2029 (USD MILLION)             231

7.4.3      DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS) 232

7.4.3.1   Declining costs of NGS-based tests to boost demand   232

TABLE 172         IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY REGION, 2021–2029 (USD MILLION)      233

TABLE 173         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021–2029 (USD MILLION)  233

TABLE 174         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021–2029 (USD MILLION)  234

TABLE 175         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021–2029 (USD MILLION)  234

TABLE 176         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, 2021–2029 (USD MILLION) 235

TABLE 177         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021–2029 (USD MILLION)  235

7.4.4      IN SITU HYBRIDIZATION (ISH) 235

7.4.4.1   Rising prevalence of cancer and genetic disorders to drive market            235

TABLE 178         IN VITRO DIAGNOSTICS MARKET FOR ISH, BY REGION, 2021–2029 (USD MILLION)     236

TABLE 179         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021–2029 (USD MILLION)            236

TABLE 180         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021–2029 (USD MILLION)    237

TABLE 181         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021–2029 (USD MILLION)    237

TABLE 182         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021–2029 (USD MILLION)            238

TABLE 183         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021–2029 (USD MILLION)            238

7.4.5      DNA MICROARRAYS      238

7.4.5.1   High resolution and throughput capabilities to support market growth     238

TABLE 184         IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2021–2029 (USD MILLION)       239

TABLE 185         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021–2029 (USD MILLION)            239

TABLE 186         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021–2029 (USD MILLION)            240

TABLE 187         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021–2029 (USD MILLION)            240

TABLE 188         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021–2029 (USD MILLION)            241

TABLE 189         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021–2029 (USD MILLION)            241

7.4.6      OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES     241

Other molecular diagnostic technologies include electrophoresis and flow cytometry.              241

TABLE 190         IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2021–2029 (USD MILLION)  242

TABLE 191         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION) 242

TABLE 192         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)          243

TABLE 193         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)          243

TABLE 194         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION) 244

TABLE 195         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION) 244

7.5         HEMATOLOGY 244

7.5.1      GROWING FOCUS ON STEM CELL RESEARCH TO BOOST DEMAND              244

TABLE 196         IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION, 2021–2029 (USD MILLION)       245

TABLE 197         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)           245

TABLE 198         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)           246

TABLE 199         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)           246

TABLE 200         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)           247

TABLE 201         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)           247

7.6         MICROBIOLOGY            247

7.6.1      RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET              247

TABLE 202         IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY REGION, 2021–2029 (USD MILLION)       248

TABLE 203         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)         248

TABLE 204         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)         249

TABLE 205         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)         249

TABLE 206         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)         250

TABLE 207         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)         250

7.7         COAGULATION & HEMOSTASIS 250

7.7.1      GROWING USE OF ANTICOAGULATION THERAPY IN SURGICAL PROCEDURES TO DRIVE MARKET          250

TABLE 208         IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2021–2029 (USD MILLION)    251

TABLE 209         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021–2029 (USD MILLION)              251

TABLE 210         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021–2029 (USD MILLION)              252

TABLE 211         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021–2029 (USD MILLION)              252

TABLE 212         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021–2029 (USD MILLION)              253

TABLE 213         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021–2029 (USD MILLION)              253

7.8         URINALYSIS      253

7.8.1      RISING INCIDENCE OF UTIS TO SUPPORT MARKET GROWTH   253

TABLE 214         IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY REGION, 2021–2029 (USD MILLION)       254

TABLE 215         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021–2029 (USD MILLION)   254

TABLE 216         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021–2029 (USD MILLION)            255

TABLE 217         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021–2029 (USD MILLION)   255

TABLE 218         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021–2029 (USD MILLION)   256

TABLE 219         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021–2029 (USD MILLION)   256

7.9         CHROMATOGRAPHY & MASS SPECTROMETRY 256

7.9.1      METHODOLOGICAL IMPROVEMENTS AND TECHNOLOGICAL INNOVATIONS TO FUEL MARKET          256

TABLE 220         IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2021–2029 (USD MILLION) 257

TABLE 221         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021–2029 (USD MILLION)          258

TABLE 222         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021–2029 (USD MILLION)          258

TABLE 223         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021–2029 (USD MILLION)          259

TABLE 224         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021–2029 (USD MILLION)          259

TABLE 225         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021–2029 (USD MILLION)          259

8            IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN            260

8.1         INTRODUCTION            261

TABLE 226         IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION) 261

8.2         BLOOD, SERUM, AND PLASMA 261

8.2.1      HIGH RELIABILITY FOR CHRONIC DISEASE DIAGNOSIS TO PROPEL MARKET            261

TABLE 227         IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021–2029 (USD MILLION)             262

TABLE 228         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021–2029 (USD MILLION)              262

TABLE 229         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021–2029 (USD MILLION) 263

TABLE 230         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021–2029 (USD MILLION) 263

TABLE 231         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021–2029 (USD MILLION)              264

TABLE 232         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021–2029 (USD MILLION)              264

8.3         SALIVA 264

8.3.1      ADVANCEMENTS IN IMMUNOASSAY-BASED TESTS TO SUPPORT MARKET GROWTH        264

TABLE 233         IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY REGION, 2021–2029 (USD MILLION)          265

TABLE 234         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021–2029 (USD MILLION)           265

TABLE 235         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021–2029 (USD MILLION)    266

TABLE 236         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021–2029 (USD MILLION)            266

TABLE 237         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021–2029 (USD MILLION)           267

TABLE 238         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021–2029 (USD MILLION)           267

8.4         URINE  267

8.4.1      INCREASING UTILIZATION IN ILLICIT DRUG TESTING TO BOOST DEMAND           267

TABLE 239         IN VITRO DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021–2029 (USD MILLION)          268

TABLE 240         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021–2029 (USD MILLION)             268

TABLE 241         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021–2029 (USD MILLION)    269

TABLE 242         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021–2029 (USD MILLION)            269

TABLE 243        LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021–2029 (USD MILLION)            270

TABLE 244         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021–2029 (USD MILLION)             270

8.5         OTHER SPECIMENS       270

TABLE 245         IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION, 2021–2029 (USD MILLION)       271

TABLE 246         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021–2029 (USD MILLION)   271

TABLE 247         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021–2029 (USD MILLION)   272

TABLE 248         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021–2029 (USD MILLION)   272

TABLE 249         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021–2029 (USD MILLION)   273

TABLE 250         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021–2029 (USD MILLION)   273

9            IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE           274

9.1         INTRODUCTION            275

TABLE 251         IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 275

9.2         LABORATORY TESTS    275

9.2.1      ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND GROWING FOCUS ON EARLY DISEASE DETECTION TO PROPEL MARKET  275

TABLE 252         IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION, 2021–2029 (USD MILLION)  276

TABLE 253         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 276

TABLE 254         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021–2029 (USD MILLION)             277

TABLE 255         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 277

TABLE 256         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 278

TABLE 257         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 278

9.3         POINT-OF-CARE TESTS 278

9.3.1      RAPID RESULTS AND HIGH CONVENIENCE TO BOOST DEMAND              278

TABLE 258         IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2021–2029 (USD MILLION)          279

TABLE 259         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021–2029 (USD MILLION)             279

TABLE 260         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021–2029 (USD MILLION)    280

TABLE 261         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021–2029 (USD MILLION)             280

TABLE 262         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021–2029 (USD MILLION)             281

TABLE 263         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021–2029 (USD MILLION)             281

10          IN VITRO DIAGNOSTICS MARKET, BY APPLICATION     282

10.1       INTRODUCTION            283

TABLE 264         IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 283

10.2       INFECTIOUS DISEASES 284

10.2.1    INCREASING PREVALENCE OF TB AND TYPHOID TO BOOST DEMAND              284

TABLE 265         IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2029 (USD MILLION)  284

TABLE 266         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)            285

TABLE 267         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)       285

TABLE 268         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)            286

TABLE 269         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)            286

TABLE 270         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)            286

10.3       ONCOLOGY      287

10.3.1    HIGH INCIDENCE OF BREAST CANCER TO PROPEL MARKET     287

TABLE 271         INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS. 2040              287

TABLE 272         IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2021–2029 (USD MILLION)       288

TABLE 273         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)  288

TABLE 274         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)            289

TABLE 275         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)  289

TABLE 276         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)  290

TABLE 277         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)  290

10.4       ENDOCRINOLOGY        290

10.4.1    RISING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO DRIVE MARKET             290

TABLE 278         IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2029 (USD MILLION)       291

TABLE 279         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)     291

TABLE 280         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)     292

TABLE 281         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)     292

TABLE 282         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)     293

TABLE 283         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)     293

10.5       CARDIOLOGY  293

10.5.1    INCREASING USE OF IMMUNOASSAYS IN CVD DETECTION TO FUEL MARKET            293

TABLE 284         IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY REGION, 2021–2029 (USD MILLION)       294

TABLE 285         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)             295

TABLE 286         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)            295

TABLE 287         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)             296

TABLE 288         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)             296

TABLE 289         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)             296

10.6       BLOOD SCREENING      297

10.6.1    RISING INCIDENCE OF HIV AND SYPHILIS TO SUPPORT MARKET GROWTH          297

TABLE 290         IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY REGION, 2021–2029 (USD MILLION)       297

TABLE 291         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021–2029 (USD MILLION)   298

TABLE 292         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021–2029 (USD MILLION)   298

TABLE 293         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021–2029 (USD MILLION)   299

TABLE 294         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021–2029 (USD MILLION)   299

TABLE 295         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021–2029 (USD MILLION)   299

10.7       GENETIC TESTING        300

10.7.1    DIAGNOSIS OF RARE DISEASES TO SUPPORT MARKET GROWTH              300

TABLE 296         IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2021–2029 (USD MILLION)       300

TABLE 297         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021–2029 (USD MILLION)    301

TABLE 298         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021–2029 (USD MILLION)        301

TABLE 299         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021–2029 (USD MILLION)        302

TABLE 300         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021–2029 (USD MILLION)    302

TABLE 301         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021–2029 (USD MILLION)    302

10.8       AUTOIMMUNE DISEASES           303

10.8.1    GROWING DEMAND FOR AUTOIMMUNITY ASSAYS TO DRIVE MARKET              303

TABLE 302         IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021–2029 (USD MILLION)           304

TABLE 303         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)        304

TABLE 304         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)        305

TABLE 305         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)        305

TABLE 306         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)        306

TABLE 307         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)        306

10.9       ALLERGY DIAGNOSTICS            306

10.9.1    ABILITY TO DETERMINE FOOD & DRUG ALLERGIES TO SUPPORT MARKET GROWTH        306

TABLE 308         IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021–2029 (USD MILLION)  307

TABLE 309         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)         307

TABLE 310         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)             308

TABLE 311         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)             308

TABLE 312         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)         309

TABLE 313         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)         309

10.10     DRUG MONITORING & TESTING            309

10.10.1  INCREASING ILLICIT DRUG CONSUMPTION TO DRIVE MARKET              309

TABLE 314         KEY PRODUCTS FOR DRUG MONITORING         310

TABLE 315         KEY IVD PRODUCTS FOR DRUG TESTING          310

TABLE 316         IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2021–2029 (USD MILLION)            311

TABLE 317         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021–2029 (USD MILLION)              311

TABLE 318         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021–2029 (USD MILLION)      312

TABLE 319         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021–2029 (USD MILLION)      312

TABLE 320         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021–2029 (USD MILLION)      313

TABLE 321         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021–2029 (USD MILLION)      313

10.11     BONE & MINERAL DISORDERS  313

10.11.1  RISING CASES OF OSTEOPOROSIS TO FUEL MARKET    313

TABLE 322         KEY PRODUCTS FOR BONE & MINERAL DISORDERS      314

TABLE 323         IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021–2029 (USD MILLION)       314

TABLE 324         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)              315

TABLE 325         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)             315

TABLE 326         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)             316

TABLE 327         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)          316

TABLE 328         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)          316

10.12     COAGULATION TESTING          317

10.12.1  INCREASING PREVALENCE OF HEMOPHILIA TO BOOST DEMAND              317

TABLE 329         IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY REGION, 2021–2029 (USD MILLION)            317

TABLE 330         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021–2029 (USD MILLION)       318

TABLE 331         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021–2029 (USD MILLION)       318

TABLE 332         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021–2029 (USD MILLION)       319

TABLE 333         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021–2029 (USD MILLION)       319

TABLE 334         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021–2029 (USD MILLION)       319

10.13     BLOOD GROUP TYPING             320

10.13.1  RISING NUMBER OF SURGICAL PROCEDURES TO SUPPORT MARKET DEMAND           320

TABLE 335        IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY REGION, 2021–2029 (USD MILLION)  321

TABLE 336         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021–2029 (USD MILLION)         321

TABLE 337         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021–2029 (USD MILLION)          322

TABLE 338         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021–2029 (USD MILLION)          322

TABLE 339         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021–2029 (USD MILLION)         323

TABLE 340         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021–2029 (USD MILLION)         323

10.14     OTHER APPLICATIONS 323

TABLE 341         IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2029 (USD MILLION)  324

TABLE 342         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION)           324

TABLE 343         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION)           325

TABLE 344         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION)           325

TABLE 345         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION)           326

TABLE 346         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION)           326

11          IN VITRO DIAGNOSTICS MARKET, BY END USER            327

11.1       INTRODUCTION            328

TABLE 347         IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 328

11.2       HOSPITALS & CLINICS  328

11.2.1    RISING INCIDENCE OF CHRONIC DISEASES TO BOOST DEMAND              328

TABLE 348         IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2029 (USD MILLION)  329

TABLE 349         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2029 (USD MILLION)            330

TABLE 350         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2029 (USD MILLION)         330

TABLE 351         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2029 (USD MILLION)            331

TABLE 352         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2029 (USD MILLION)            331

TABLE 353         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2029 (USD MILLION)            331

11.3       CLINICAL LABORATORIES         332

TABLE 354         IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     332

TABLE 355         IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2029 (USD MILLION) 333

TABLE 356         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)     333

TABLE 357         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)          334

TABLE 358         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)          334

TABLE 359         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)     335

TABLE 360         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)     335

11.3.1    LARGE REFERENCE LABORATORIES      335

11.3.1.1 Capability to conduct specific advanced tests to propel market   335

TABLE 361         IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2021–2029 (USD MILLION) 336

TABLE 362         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)              336

TABLE 363         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)  337

TABLE 364         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)  337

TABLE 365         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)  338

TABLE 366         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)              338

11.3.2    SMALL AND MEDIUM-SIZED LABORATORIES    338

11.3.2.1 Growing focus on POC device adoption to support market growth           338

TABLE 367         IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY REGION, 2021–2029 (USD MILLION)  339

TABLE 368         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)          339

TABLE 369         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)              340

TABLE 370         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)              340

TABLE 371         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)              341

TABLE 372         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)          341

11.4       BLOOD BANKS 341

11.4.1    RISING UTILIZATION OF ELISA TESTS TO PROPEL MARKET      341

TABLE 373         IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY REGION, 2021–2029 (USD MILLION)       342

TABLE 374         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2029 (USD MILLION)            342

TABLE 375         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2029 (USD MILLION)            343

TABLE 376         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2029 (USD MILLION)            343

TABLE 377         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2029 (USD MILLION)            344

TABLE 378         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2029 (USD MILLION)            344

11.5       HOME CARE SETTINGS 344

11.5.1    ADOPTION OF CONVENIENT AT-HOME ANTIGEN TESTS TO BOOST DEMAND           344

TABLE 379         IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2029 (USD MILLION)  345

TABLE 380         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2029 (USD MILLION)           346

TABLE 381         EUROPE: IVD MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2029 (USD MILLION)    346

TABLE 382         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2029 (USD MILLION)         347

TABLE 383         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2029 (USD MILLION)         347

TABLE 384         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2029 (USD MILLION)           347

11.6       PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES   348

11.6.1    INCREASING FOCUS ON DRUG DISCOVERY DEVELOPMENT TO DRIVE MARKET            348

TABLE 385         IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2029 (USD MILLION) 349

TABLE 386         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2029 (USD MILLION) 349

TABLE 387         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2029 (USD MILLION) 350

TABLE 388         ASIA PACIFIC: IVD MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2029 (USD MILLION)              350

TABLE 389         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2029 (USD MILLION) 351

TABLE 390         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2029 (USD MILLION) 351

11.7       ACADEMIC INSTITUTES             351

11.7.1    RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO SUPPORT MARKET GROWTH          351

TABLE 391        IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021–2029 (USD MILLION)  352

TABLE 392         NORTH AMERICA: IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2029 (USD MILLION)            352

TABLE 393         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2029 (USD MILLION)  353

TABLE 394         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2029 (USD MILLION)         353

TABLE 395         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2029 (USD MILLION)         354

TABLE 396         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2029 (USD MILLION)         354

11.8       OTHER END USERS        354

TABLE 397         IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2029 (USD MILLION)       355

TABLE 398         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION)    355

TABLE 399         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION)             356

TABLE 400         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION)    356

TABLE 401         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION)    357

TABLE 402         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION)    357

12          IN VITRO DIAGNOSTICS MARKET, BY REGION  358

12.1       INTRODUCTION            359

TABLE 403         IN VITRO DIAGNOSTICS MARKET, BY REGION, 2021–2029 (USD MILLION)          359

12.2       NORTH AMERICA          360

12.2.1    NORTH AMERICA: RECESSION IMPACT 360

FIGURE 34         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET SNAPSHOT        361

TABLE 404         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)    361

TABLE 405         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)            362

TABLE 406         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          362

TABLE 407         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   363

TABLE 408         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)       363

TABLE 409         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)           364

TABLE 410         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)   364

TABLE 411         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)             365

TABLE 412         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)           365

TABLE 413         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)             366

TABLE 414         NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION) 366

12.2.2    US         367

12.2.2.1 Established reimbursement framework and favorable policies for IVD providers to drive market        367

TABLE 415         US: MACROECONOMIC INDICATORS    368

TABLE 416         US: NUMBER OF IN VITRO TESTS CONDUCTED (BILLION)              368

TABLE 417        US: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)          369

TABLE 418         US: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)     369

TABLE 419         US: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)             370

TABLE 420         US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            370

TABLE 421         US: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        371

TABLE 422         US: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION) 371

TABLE 423         US: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 371

TABLE 424         US: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)     372

TABLE 425         US: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 373

TABLE 426         US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     373

12.2.3    CANADA            373

12.2.3.1 Favorable funding initiatives for early disease diagnosis to drive market   373

TABLE 427         CANADA: ESTIMATED PREVALENCE OF DIABETES        374

TABLE 428         CANADA: MACROECONOMIC INDICATORS       375

TABLE 429         CANADA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)       375

TABLE 430        CANADA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          376

TABLE 431         CANADA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   376

TABLE 432         CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            377

TABLE 433         CANADA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        377

TABLE 434         CANADA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)          378

TABLE 435         CANADA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)          378

TABLE 436         CANADA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          379

TABLE 437         CANADA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)          380

TABLE 438         CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     380

12.3       EUROPE             380

12.3.1    EUROPE: RECESSION IMPACT   381

TABLE 439         EUROPE: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)          382

TABLE 440         EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)       382

TABLE 441         EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          383

TABLE 442         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   383

TABLE 443         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            384

TABLE 444         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        384

TABLE 445         EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)          385

TABLE 446         EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)          385

TABLE 447         EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          386

TABLE 448         EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)          387

TABLE 449         EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     387

12.3.2    GERMANY         388

12.3.2.1 Increasing investments in clinical diagnostics research to drive market     388

TABLE 450         GERMANY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)       389

TABLE 451         GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          389

TABLE 452         GERMANY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   390

TABLE 453         GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            390

TABLE 454         GERMANY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)           391

TABLE 455         GERMANY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)          391

TABLE 456         GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)          391

TABLE 457         GERMANY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)           392

TABLE 458         GERMANY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)          393

TABLE 459         GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     393

12.3.3    FRANCE             394

12.3.3.1 High healthcare expenditure and rising investments in genomic medicine to drive market   394

TABLE 460         FRANCE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)       394

TABLE 461         FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          395

TABLE 462         FRANCE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   395

TABLE 463         FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            396

TABLE 464         FRANCE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        396

TABLE 465         FRANCE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)          397

TABLE 466         FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)          397

TABLE 467         FRANCE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          398

TABLE 468         FRANCE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)          399

TABLE 469         FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     399

12.3.4    UK         399

12.3.4.1 Rising adoption of genome-based testing to drive market           399

TABLE 470         UK: MACROECONOMIC INDICATORS    401

TABLE 471        UK: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)          401

TABLE 472         UK: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)     402

TABLE 473         UK: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)       402

TABLE 474         UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            403

TABLE 475         UK: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        403

TABLE 476         UK: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION) 404

TABLE 477         UK: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)     404

TABLE 478         UK: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)     405

TABLE 479         UK: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 406

TABLE 480         UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     406

12.3.5    ITALY   406

12.3.5.1 Growing geriatric population and subsequent rise in chronic conditions to support market growth     406

TABLE 481         ITALY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)       407

TABLE 482         ITALY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          408

TABLE 483        ITALY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)       408

TABLE 484         ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            409

TABLE 485         ITALY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        409

TABLE 486         ITALY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)     410

TABLE 487         ITALY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)     410

TABLE 488         ITALY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          411

TABLE 489         ITALY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)     411

TABLE 490         ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     412

12.3.6    SPAIN   412

12.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market              412

TABLE 491         SPAIN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)       413

TABLE 492         SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          413

TABLE 493        SPAIN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)       414

TABLE 494         SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            414

TABLE 495         SPAIN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        415

TABLE 496         SPAIN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)     415

TABLE 497         SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)     415

TABLE 498         SPAIN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          416

TABLE 499         SPAIN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)     416

TABLE 500         SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     417

12.3.7    RUSSIA 417

12.3.7.1 High incidence of respiratory infectious diseases to boost demand           417

TABLE 501         RUSSIA: MACROECONOMIC INDICATORS          418

TABLE 502         RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)       418

TABLE 503         RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          419

TABLE 504         RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   419

TABLE 505         RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            420

TABLE 506         RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        420

TABLE 507         RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)     421

TABLE 508         RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)          421

TABLE 509         RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          422

TABLE 510         RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)     422

TABLE 511         RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     423

12.3.8    SWITZERLAND 423

12.3.8.1 Rising prevalence of chronic diseases to support market growth 423

TABLE 512         SWITZERLAND: MACROECONOMIC INDICATORS          424

TABLE 513         SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)            424

TABLE 514         SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          425

TABLE 515         SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   425

TABLE 516         SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)       426

TABLE 517         SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)           426

TABLE 518         SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)   427

TABLE 519         SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)             427

TABLE 520         SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)           428

TABLE 521         SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)             429

TABLE 522         SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION) 429

12.3.9    REST OF EUROPE           429

TABLE 523         REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)            430

TABLE 524         REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          431

TABLE 525         REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   431

TABLE 526         REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)       432

TABLE 527         REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)           432

TABLE 528         REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)   433

TABLE 529         REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)             433

TABLE 530         REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)           434

TABLE 531         REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)             435

TABLE 532         REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION) 435

12.4       ASIA PACIFIC    436

FIGURE 35         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET SNAPSHOT              437

TABLE 533         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)          438

TABLE 534         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)   438

TABLE 535         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          439

TABLE 536         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   439

TABLE 537         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            440

TABLE 538         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)           440

TABLE 539        ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)          441

TABLE 540        ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)          441

TABLE 541         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)           442

TABLE 542         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)          443

TABLE 543         ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     443

12.4.1    ASIA PACIFIC: RECESSION IMPACT        444

12.4.2    JAPAN  444

12.4.2.1 Increasing research investments for immunoassays to drive market          444

TABLE 544         JAPAN: MACROECONOMIC INDICATORS            445

TABLE 545         JAPAN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)       445

TABLE 546         JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          446

TABLE 547        JAPAN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)       446

TABLE 548         JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            447

TABLE 549         JAPAN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        447

TABLE 550         JAPAN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)     448

TABLE 551         JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)     448

TABLE 552         JAPAN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          449

TABLE 553         JAPAN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)     449

TABLE 554         JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     450

12.4.3    CHINA  450

12.4.3.1 Growing focus on preventive care to boost demand      450

TABLE 555         CHINA: MACROECONOMIC INDICATORS           451

TABLE 556         CHINA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)       451

TABLE 557         CHINA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          451

TABLE 558         CHINA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   452

TABLE 559         CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            452

TABLE 560         CHINA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        453

TABLE 561         CHINA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)     453

TABLE 562         CHINA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)     453

TABLE 563         CHINA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          454

TABLE 564         CHINA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)     454

TABLE 565         CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     455

12.4.4    INDIA   455

12.4.4.1 Rising incidence of diabetes and cancer to drive market             455

TABLE 566         INDIA: MACROECONOMIC INDICATORS            456

TABLE 567         INDIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)       456

TABLE 568         INDIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          457

TABLE 569        INDIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)       457

TABLE 570         INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            458

TABLE 571         INDIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        458

TABLE 572         INDIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)     459

TABLE 573         INDIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)     459

TABLE 574         INDIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          460

TABLE 575         INDIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)     460

TABLE 576         INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     461

12.4.5    SOUTH KOREA 461

12.4.5.1 Rising healthcare spending for innovative IVD technologies to support market growth   461

TABLE 577         SOUTH KOREA: MACROECONOMIC INDICATORS          462

TABLE 578         SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)            462

TABLE 579         SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          463

TABLE 580         SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   463

TABLE 581         SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)       464

TABLE 582         SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)           464

TABLE 583         SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)   465

TABLE 584         SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)             465

TABLE 585         SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)           466

TABLE 586         SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)             467

TABLE 587         SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION) 467

12.4.6    AUSTRALIA       467

12.4.6.1 Increasing incidence of chronic diseases and rising blood donations to fuel market              467

TABLE 588         AUSTRALIA: MACROECONOMIC INDICATORS  468

TABLE 589         AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)       468

TABLE 590         AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          469

TABLE 591         AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   469

TABLE 592         AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            470

TABLE 593         AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)           470

TABLE 594         AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)          471

TABLE 595         AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)          471

TABLE 596         AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)           472

TABLE 597         AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)          473

TABLE 598         AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     473

12.4.7    REST OF ASIA PACIFIC  474

TABLE 599         REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)            474

TABLE 600         REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          475

TABLE 601         REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   475

TABLE 602         REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)       476

TABLE 603         REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)           476

TABLE 604         REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)   477

TABLE 605         REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)  477

TABLE 606         REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)           478

TABLE 607         REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)    479

TABLE 608         REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION) 479

12.5       LATIN AMERICA             480

12.5.1    LATIN AMERICA: RECESSION IMPACT   480

TABLE 609         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)    480

TABLE 610         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)            481

TABLE 611         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          481

TABLE 612         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   482

TABLE 613         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)       482

TABLE 614         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)           483

TABLE 615         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)   483

TABLE 616         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)             484

TABLE 617         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)           484

TABLE 618         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)             485

TABLE 619         LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION) 485

12.5.2    BRAZIL 486

12.5.2.1 Rising prevalence of diabetes to boost demand for IVD products             486

TABLE 620         BRAZIL: MACROECONOMIC INDICATORS          486

TABLE 621         BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)       487

TABLE 622         BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          487

TABLE 623         BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   488

TABLE 624         BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            488

TABLE 625         BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        489

TABLE 626         BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)     489

TABLE 627         BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)          489

TABLE 628         BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          490

TABLE 629         BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)     490

TABLE 630         BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     491

12.5.3    MEXICO             491

12.5.3.1 Establishment of clinical laboratories to fuel uptake     491

TABLE 631         MEXICO: MACROECONOMIC INDICATORS        492

TABLE 632         MEXICO: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)       492

TABLE 633         MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          493

TABLE 634         MEXICO: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   493

TABLE 635         MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)            494

TABLE 636         MEXICO: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)        494

TABLE 637         MEXICO: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)          495

TABLE 638         MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)          495

TABLE 639         MEXICO: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)          496

TABLE 640         MEXICO: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)          496

TABLE 641         MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)     497

12.5.4    REST OF LATIN AMERICA          497

TABLE 642         REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)      498

TABLE 643         REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)    498

TABLE 644         REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)         499

TABLE 645         REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)             499

TABLE 646         REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)   500

TABLE 647         REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)            500

TABLE 648         REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)           501

TABLE 649         REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)     501

TABLE 650         REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)            502

TABLE 651         REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)      502

12.6       MIDDLE EAST & AFRICA             503

12.6.1    GROWING FOCUS ON PRENATAL & CANCER TESTING TO DRIVE MARKET            503

TABLE 652         MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)            503

TABLE 653         MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          504

TABLE 654         MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)         504

TABLE 655         MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)             505

TABLE 656         MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)   505

TABLE 657         MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)   506

TABLE 658         MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)  506

TABLE 659         MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)           507

TABLE 660         MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)    508

TABLE 661         MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)      508

12.6.2    MIDDLE EAST & AFRICA: RECESSION IMPACT   508

12.7       GCC COUNTRIES           509

12.7.1    GCC COUNTRIES: RECESSION IMPACT 509

TABLE 662         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)    510

TABLE 663         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)            510

TABLE 664         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)          511

TABLE 665         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)   511

TABLE 666         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)       512

TABLE 667         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)           512

TABLE 668         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)   513

TABLE 669         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)             513

TABLE 670         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)           514

TABLE 671         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)             515

TABLE 672         GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION) 515

12.7.2    KINGDOM OF SAUDI ARABIA (KSA)       515

12.7.2.1 Rising government healthcare expenditure to boost demand      515

TABLE 673         KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)   516

TABLE 674         KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 516

TABLE 675         KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)       517

TABLE 676         KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)              517

TABLE 677         KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)              518

TABLE 678         KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)        518

TABLE 679         KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)       519

TABLE 680         KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)  519

TABLE 681         KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)         520

TABLE 682         KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)              520

12.7.3    UNITED ARAB EMIRATES (UAE)             521

12.7.3.1 Improvements in healthcare infrastructure to support market growth       521

TABLE 683         UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)      521

TABLE 684         UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)    522

TABLE 685         UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)         522

TABLE 686         UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)             523

TABLE 687         UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)   523

TABLE 688         UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)            524

TABLE 689         UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)           524

TABLE 690         UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)     525

TABLE 691         UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)            526

TABLE 692         UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)      526

12.7.4    OTHER GCC COUNTRIES           527

TABLE 693         OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)      527

TABLE 694         OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)    528

TABLE 695         OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)         528

TABLE 696         OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)             529

TABLE 697         OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)   529

TABLE 698         OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)            530

TABLE 699         OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)           530

TABLE 700         OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)     531

TABLE 701         OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)            532

TABLE 702         OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)      532

13          COMPETITIVE LANDSCAPE       533

13.1       OVERVIEW        533

13.2       STRATEGIES ADOPTED BY KEY PLAYERS           533

TABLE 703         OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN IVD MARKET    534

13.3       REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS      535

FIGURE 36         REVENUE SHARE ANALYSIS OF KEY PLAYERS IN IVD MARKET              535

13.4       MARKET SHARE ANALYSIS         536

TABLE 704         IN VITRO DIAGNOSTICS MARKET: INTENSITY OF COMPETITIVE RIVALRY             536

FIGURE 37         IN VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2023)   537

13.5       COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023   538

13.5.1    STARS  538

13.5.2    EMERGING LEADERS    538

13.5.3    PERVASIVE PLAYERS     538

13.5.4    PARTICIPANTS 538

FIGURE 38         COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2023              539

13.5.5    COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS       540

TABLE 705         COMPANY FOOTPRINT ANALYSIS         540

TABLE 706         COMPANY PRODUCT & SERVICE FOOTPRINT   541

TABLE 707         COMPANY TECHNOLOGY FOOTPRINT 542

TABLE 708         COMPANY APPLICATION FOOTPRINT  543

13.6       START UP/SME EVALUATION MATRIX, 2023      544

13.6.1    PROGRESSIVE COMPANIES       544

13.6.2    RESPONSIVE COMPANIES          544

13.6.3    DYNAMIC COMPANIES 544

13.6.4    STARTING BLOCKS       544

FIGURE 39         COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2023              545

13.6.5    COMPETITIVE BENCHMARKING OF START-UPS/SMES  545

TABLE 709         IN VITRO DIAGNOSTICS MARKET: KEY START-UPS/SMES              545

13.7       COMPETITIVE SCENARIO          546

13.7.1    PRODUCT & SERVICE LAUNCHES AND APPROVALS       546

TABLE 710         IN VITRO DIAGNOSTICS MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS (JANUARY 2020–JANUARY 2024)    546

13.7.2    DEALS  547

TABLE 711         IN VITRO DIAGNOSTICS MARKET: DEALS (JANUARY 2020–JANUARY 2024) 547

13.7.3    EXPANSIONS    548

TABLE 712         IN VITRO DIAGNOSTICS MARKET: EXPANSIONS (JANUARY 2020−JANUARY 2024)    548

13.7.4    OTHER DEVELOPMENTS           549

TABLE 713         IN VITRO DIAGNOSTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2020−JANUARY 2024)             549

13.8       BRAND/PRODUCT COMPARISON          550

TABLE 714         BRAND/PRODUCT COMPARISON FOR IN VITRO DIAGNOSTICS INSTRUMENTS 550

14          COMPANY PROFILES    551

14.1       KEY PLAYERS   551

(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*

14.1.1    DANAHER CORPORATION         551

TABLE 715         DANAHER: COMPANY OVERVIEW          551

FIGURE 40         DANAHER: COMPANY SNAPSHOT (2023)            552

14.1.2    ROCHE DIAGNOSTICS  558

TABLE 716         ROCHE DIAGNOSTICS: COMPANY OVERVIEW   558

FIGURE 41         ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2023)     558

14.1.3    ABBOTT            568

TABLE 717         ABBOTT: COMPANY OVERVIEW             568

FIGURE 42         ABBOTT: COMPANY SNAPSHOT (2023) 569

14.1.4    SIEMENS HEALTHINEERS AG    576

TABLE 718         SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW     576

FIGURE 43         SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)              577

14.1.5    THERMO FISHER SCIENTIFIC INC.          583

TABLE 719         THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW              583

FIGURE 44         THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)   584

14.1.6    ILLUMINA, INC. 591

TABLE 720         ILLUMINA, INC.: COMPANY OVERVIEW 591

FIGURE 45         ILLUMINA, INC.: COMPANY SNAPSHOT (2023)  592

4.1.7      HOLOGIC, INC. 597

TABLE 721         HOLOGIC, INC.: COMPANY OVERVIEW 597

FIGURE 46         HOLOGIC, INC.: COMPANY SNAPSHOT (2023)   598

14.1.8    BIO-RAD LABORATORIES, INC. 601

TABLE 722         BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW  601

FIGURE 47         BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)              602

14.1.9    BIOMÉRIEUX    606

TABLE 723         BIOMÉRIEUX: COMPANY OVERVIEW     606

FIGURE 48         BIOMÉRIEUX: COMPANY SNAPSHOT (2023)       607

14.1.10  SYSMEX CORPORATION             612

TABLE 724         SYSMEX CORPORATION: COMPANY OVERVIEW 612

FIGURE 49         SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)  612

14.1.11  REVVITY            616

TABLE 725         REVVITY: COMPANY OVERVIEW            616

FIGURE 50         REVVITY: COMPANY SNAPSHOT (2023) 617

14.1.12  BECTON, DICKINSON AND COMPANY  622

TABLE 726         BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW              622

FIGURE 51         BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)   623

14.1.13  AGILENT TECHNOLOGIES, INC.             628

TABLE 727         AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 628

FIGURE 52         AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)              629

14.1.14  QIAGEN N.V.     635

TABLE 728         QIAGEN N.V.: COMPANY OVERVIEW     635

FIGURE 53         QIAGEN N.V.: COMPANY SNAPSHOT (2023)        636

14.1.15  DIASORIN S.P.A.             644

TABLE 729         DIASORIN S.P.A: COMPANY OVERVIEW 644

FIGURE 54         DIASORIN S.P.A: COMPANY SNAPSHOT (2023)   645

14.1.16  GRIFOLS S.A      652

TABLE 730         GRIFOLS S.A: COMPANY OVERVIEW      652

FIGURE 55         GRIFOLS S.A: COMPANY SNAPSHOT (2023)        652

14.1.17  WERFEN S.A.     655

TABLE 731         WERFEN S.A: COMPANY OVERVIEW       655

FIGURE 56         WERFEN S.A: COMPANY SNAPSHOT (2023)         656

14.1.18  QUIDELORTHO CORPORATION             659

TABLE 732         QUIDELORTHO CORPORATION: COMPANY OVERVIEW 659

FIGURE 57         QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2023)              660

14.2       OTHER PLAYERS           666

14.2.1    DEVYSER           666

TABLE 733         DEVYSER: COMPANY OVERVIEW            666

FIGURE 58         DEVYSER: COMPANY SNAPSHOT (2023) 666

14.2.2    CHEMBIO DIAGNOSTICS, INC.  668

TABLE 734         CHEMBIO DIAGNOSTICS, INC.: COMPANY OVERVIEW   668

FIGURE 59         CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)              668

14.2.3    SURMODICS, INC.          671

TABLE 735         SURMODICS, INC.: COMPANY OVERVIEW           671

FIGURE 60         SURMODICS, INC.: COMPANY SNAPSHOT (2023)             672

14.2.4    MENARINI SILICON BIOSYSTEMS           674

TABLE 736         MENARINI SILICON BIOSYSTEMS: COMPANY OVERVIEW              674

14.2.5    SPEEDX PTY. LTD.         675

TABLE 737         SPEEDX PTY. LTD.: COMPANY OVERVIEW          675

14.2.6    GENSPEED BIOTECH GMBH      676

TABLE 738         GENSPEED BIOTECH GMBH: COMPANY OVERVIEW      676

14.2.7    MERCK KGAA   677

TABLE 739         MERCK KGAA: COMPANY OVERVIEW    677

14.2.8    CARIS LIFE SCIENCES, INC.        679

TABLE 740         CARIS LIFE SCIENCES, INC.: COMPANY OVERVIEW         679

14.2.9    ARKRAY, INC.    681

TABLE 741         ARKRAY, INC.: COMPANY OVERVIEW    681

14.2.10  ACCELERATE DIAGNOSTICS, INC.          682

TABLE 742         ACCELERATE DIAGNOSTICS, INC.: COMPANY OVERVIEW              682

14.2.11  CELLABS           683

TABLE 743         CELLABS: COMPANY OVERVIEW            683

14.2.12  J. MITRA & CO. PVT. LTD.           684

TABLE 744         MITRA & CO. PVT. LTD.: COMPANY OVERVIEW 684

14.2.13  EPITOPE DIAGNOSTICS, INC.    685

TABLE 745         EPITOME DIAGNOSTICS, INC.: COMPANY OVERVIEW   685

14.2.14  BOSTER BIOLOGICAL TECHNOLOGY   686

TABLE 746         BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW              686

14.2.15  ENZO BIOCHEM, INC.    687

TABLE 747         ENZO BIOCHEM, INC: COMPANY OVERVIEW     687

14.2.16  GENETIC SIGNATURES 688

TABLE 748         GENETIC SIGNATURES: COMPANY OVERVIEW 688

14.2.17  SAVYON DIAGNOSTICS LTD.    689

TABLE 749         SAVYON DIAGNOSTICS LTD.: COMPANY OVERVIEW     689

14.2.18  TRIVITRON HEALTHCARE         690

TABLE 750         TRIVITRON HEALTHCARE: COMPANY OVERVIEW          690

14.2.19  MDXHEALTH SA            691

TABLE 751         MDXHEALTH SA: COMPANY OVERVIEW             691

14.2.20  CREATIVE DIAGNOSTICS           692

TABLE 752         CREATIVE DIAGNOSTICS: COMPANY OVERVIEW           692

14.2.21  INBIOS INTERNATIONAL, INC.  693

TABLE 753         INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW  693

14.2.22  MACCURA BIOTECHNOLOGY CO., LTD.             694

TABLE 754         MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW              694

14.2.23  VELA DIAGNOSTICS     695

TABLE 755         VELA DIAGNOSTICS: COMPANY OVERVIEW      695

*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.

15          APPENDIX         696

15.1       DISCUSSION GUIDE      696

15.2       KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             703

15.3       CUSTOMIZATION OPTIONS      705

15.4       RELATED REPORTS       706

15.5       AUTHOR DETAILS         707